This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Basilea Appoints New Chief Financial Officer

BASEL, Switzerland, Nov. 4, 2013 (GLOBE NEWSWIRE) --
Basilea Pharmaceutica Ltd. (SIX: BSLN)
announced today the promotion of Mr. Donato Spota to Chief Financial Officer of
the Company, effective today. As a member of the management committee, he will
be responsible for finance, information technology, and internal services. Mr.
Spota has served as Global Head of Finance and Services since February 2013.
Prior to this position, Mr. Spota acted as Head of Basilea's Global Controlling
since 2002.

Ronald Scott, Chief Executive Officer of Basilea, stated: "Donato Spota has been
with the company for over ten years. He has demonstrated exceptional execution
in leading Basilea's finance and controlling functions. He was instrumental in
establishing Basilea's finance organization and has been a key participant in
all our major financing and partnering transactions. I am confident that with
his longstanding financial and operational experience Donato will continue to
significantly contribute to lead our business forward."

Mr. Spota holds a master degree in business administration from the University
of Applied Sciences Nürtingen, Germany and a diploma in information technology
from SFBI (Staatssekretariat für Bildung, Forschung und Innovation),
Switzerland. He has over 16 years of experience as a finance professional in the
pharmaceutical industry, including with F. Hoffmann-La Roche prior to joining
Basilea.

About Basilea

Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed on
the SIX Swiss Exchange (SIX: BSLN). Through the fully integrated research and
development operations of its Swiss subsidiary Basilea Pharmaceutica
International Ltd., the company focuses on innovative pharmaceutical products in
the therapeutic areas of bacterial infections, fungal infections and oncology,
targeting the medical challenge of rising resistance and non-response to current
treatment options.

Disclaimer

This communication expressly or implicitly contains certain forward-looking
statements concerning Basilea Pharmaceutica Ltd. and its business. Such
statements involve certain known and unknown risks, uncertainties and other
factors, which could cause the actual results, financial condition, performance
or achievements of Basilea Pharmaceutica Ltd. to be materially different from
any future results, performance or achievements expressed or implied by such
forward-looking statements. Basilea Pharmaceutica Ltd. is providing this
communication as of this date and does not undertake to update any forward-
looking statements contained herein as a result of new information, future
events or otherwise.

For further information, please contact:

+-----------------------------+--------------------------------+
| Media Relations             | Investor Relations             |
+-----------------------------+--------------------------------+
| Peer Nils Schröder, PhD     | Barbara Zink, PhD, MBA         |
| Head Public Relations &     | Head Corporate Development     |
| Corporate Communications    |                                |
| +41 61 606 1102             | +41 61 606 1233                |
| media_relations@basilea.com | investor_relations@basilea.com |
+-----------------------------+--------------------------------+
This press release can be downloaded from www.basilea.com.


Press release (PDF): http://hugin.info/134390/R/1740094/584178.pdf

[HUG#1740094]

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,602.64 +4.44 0.03%
S&P 500 2,100.59 +2.55 0.12%
NASDAQ 5,121.4270 +6.0450 0.12%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs